Loading organizations...
Loading organizations...
Gene coding company developing curative therapies for inherited disorders.
SalioGen Therapeutics has raised $135.0M across 2 funding rounds.
SalioGen Therapeutics has raised $135.0M in total across 2 funding rounds.
SalioGen Therapeutics has raised $135.0M in total across 2 funding rounds.
SalioGen Therapeutics's investors include EPIQ Capital Group, Craig Gordon, Martin Mense, D1 Capital Partners, Fidelity Management & Research Company, PBM Capital, RD Fund, SymBiosis, T. Rowe Price Associates, Sean Stalfort.
SalioGen Therapeutics has raised $135.0M across 2 funding rounds. Most recently, it raised $115.0M Series B in January 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 5, 2022 | $115.0M Series B | EPIQ Capital Group, Craig Gordon | Martin Mense, D1 Capital Partners, Fidelity Management & Research Company, PBM Capital, RD Fund, SymBiosis, T. Rowe Price Associates |
| Mar 1, 2021 | $20.0M Series A | Sean Stalfort |